STOCK TITAN

PolyPid Ltd. (PYPD) Financials

PYPD NASDAQ
FY2025 annual
Net Income -$34.2M n/m YoY
EPS (Diluted) -$2.09 YoY not available
Free Cash Flow -$28.1M n/m YoY
Operating Cash Flow -$27.9M n/m YoY
Market Cap $129.3M as of Nov 20, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 11.8x on $11.0M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Feb 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PYPD SEC filings page.

This page shows PolyPid Ltd. (PYPD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for PolyPid Ltd., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

PolyPid Ltd. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

PolyPid Ltd. reported a net loss of $34.2M while operations used $27.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

PolyPid Ltd. reported an operating loss of $33.0M against $874K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$31.5M
YoYn/m
5Y CAGRn/m

PolyPid Ltd.'s EBITDA was -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.

Net Income
-$34.2M
YoYn/m
5Y CAGRn/m

PolyPid Ltd. reported a net loss of $34.2M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.

EPS (Diluted)
-$2.09

PolyPid Ltd. earned -$2.09 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
-$28.1M
YoYn/m
5Y CAGRn/m

PolyPid Ltd. recorded an outflow of $28.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.

Cash & Debt
$6.4M
YoY-59.1%
5Y CAGR+8.2%

PolyPid Ltd. held $6.4M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
18M

PolyPid Ltd. had 18M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity
-311.4%
YoY+66.3pp

PolyPid Ltd.'s ROE was -311.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 66.3 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending
$23.8M
YoY+4.4%
5Y CAGR+7.0%

PolyPid Ltd. invested $23.8M in research and development in fiscal year 2025. This represents an increase of 4.4% from the prior year.

Capital Expenditures
$210K
YoY+176.3%
5Y CAGR-23.1%

PolyPid Ltd. invested $210K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 176.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

PYPD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PYPD annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-F
R&D Expenses$23.8M+4.4%$22.8M+41.3%$16.1M-42.3%$28.0M-8.4%$30.6M+80.2%$17.0M+20.4%$14.1M+12.2%$12.6M
SG&A Expenses$7.2M+68.1%$4.3M-22.6%$5.5M-31.0%$8.0M-16.6%$9.6M+24.7%$7.7M+114.6%$3.6M-31.8%$5.3M
Operating Income-$33.0Mn/m-$28.0Mn/m-$22.9Mn/m-$38.9Mn/m-$43.1Mn/m-$26.3Mn/m-$18.6Mn/m-$18.4M
EBITDA-$31.5Mn/m-$26.4Mn/m-$21.0Mn/m-$37.2Mn/m-$42.0Mn/m-$25.3Mn/m-$17.6Mn/m-$18.0M
Interest Expense$874K-42.1%$1.5M-6.7%$1.6M+58.2%$1.0MN/AN/AN/AN/A
Income Tax$5K-88.1%$42K-39.1%$69K-46.5%$129KN/AN/AN/AN/A
Net Income-$34.2Mn/m-$29.0Mn/m-$23.9Mn/m-$39.6Mn/m-$42.6Mn/m-$36.9Mn/m-$6.9M-216.7%$5.9M
EPS (Basic)-$2.09-$4.91-$16.99-$61.09-189.5%$68.27$134.40$710.70n/m-$4.80
EPS (Diluted)-$2.09-$4.91-$16.93-$61.09-189.5%$68.27$134.40$710.70+2654.7%$25.80
Diluted Shares (Avg)16M6M1M647,556+3.8%624,051319,41418,748-8.3%20,445

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

PYPD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PYPD annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-F
Total Assets$22.3M-11.6%$25.2M+64.1%$15.4M-40.8%$26.0M-41.3%$44.2M-41.7%$75.8M+124.7%$33.8MN/A
Current Assets$15.2M-8.1%$16.6M+173.2%$6.1M-57.3%$14.2M-59.2%$34.8M-26.2%$47.2M+72.3%$27.4MN/A
Cash & Equivalents$6.4M-59.1%$15.6M+194.6%$5.3M-37.9%$8.6M-12.9%$9.8M+127.3%$4.3M+10.1%$3.9M-49.5%$7.8M
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
Long-Term Investments$0n/m$0-100.0%$9.3M-21.0%$11.8M+25.0%$9.4M-67.1%$28.6M+351.1%$6.4Mn/m$0
Total Liabilities$11.3M-35.4%$17.5M+0.4%$17.5M-13.3%$20.1M+143.4%$8.3M+169.5%$3.1M-97.5%$121.4MN/A
Current Liabilities$7.7M-39.0%$12.7M+74.0%$7.3M-14.8%$8.6M+5.9%$8.1M+180.7%$2.9M+11.6%$2.6MN/A
Non-Current Liabilities$3.6M-26.0%$4.9M-52.3%$10.2M-12.1%$11.6M+5723.6%$199K+3.1%$193K-99.8%$118.8MN/A
Long-Term DebtN/A$634K-90.1%$6.4M-15.8%$7.6MN/AN/AN/AN/A
Total Equity$11.0M+42.8%$7.7Mn/m-$2.1M-136.0%$5.8M-83.8%$36.0M-50.6%$72.8Mn/m-$87.6Mn/m-$81.7M
Retained Earnings-$301.5Mn/m-$267.3Mn/m-$238.3Mn/m-$214.4Mn/m-$174.9Mn/m-$132.3Mn/m-$93.3MN/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

PYPD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PYPD annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-F
Operating Cash Flow-$27.9Mn/m-$22.0Mn/m-$17.2Mn/m-$34.3Mn/m-$32.4Mn/m-$21.6Mn/m-$17.4Mn/m-$16.7M
Depreciation & Amortization$1.5M-10.1%$1.6M-11.0%$1.8M+5.9%$1.7M+53.9%$1.1M+10.5%$1.0M+6.9%$947K+130.4%$411K
Stock-Based Compensation$4.9M+71.9%$2.8M-16.7%$3.4M-21.3%$4.3M-9.3%$4.8M+3.8%$4.6M+369.0%$976K-1.9%$995K
Capital Expenditures$210K+176.3%$76K-61.2%$196K-88.9%$1.8M-33.4%$2.7M+239.7%$781K-11.1%$879K-71.4%$3.1M
Free Cash Flow-$28.1Mn/m-$22.0Mn/m-$17.4Mn/m-$36.1Mn/m-$35.0Mn/m-$22.4Mn/m-$18.2Mn/m-$19.8M
Investing Cash Flow-$6.7Mn/m-$330K-108.7%$3.8M-77.0%$16.6M-55.1%$36.9Mn/m-$40.8Mn/m-$23.6M-315.1%$11.0M
Financing Cash Flow$25.4M-21.7%$32.4M+224.9%$10.0M-39.3%$16.4M+1488.8%$1.0M-98.4%$62.8M+66.7%$37.7M+301.1%$9.4M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PYPD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PYPD annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-F
Return on Equity-311.4%+66.3pp-377.7%N/A-678.6%-560.1pp-118.5%-67.8pp-50.7%N/AN/A
Return on Assets-153.2%-38.1pp-115.1%+40.2pp-155.3%-2.9pp-152.3%-56.0pp-96.3%-47.7pp-48.6%-28.1pp-20.5%N/A
Current Ratio1.97+0.7x1.31+0.5x0.83-0.8x1.66-2.7x4.31-12.1x16.41+5.8x10.62N/A
Debt-to-EquityN/A0.08N/A1.30N/AN/AN/AN/A
Liabilities-to-Equity1.03-1.2x2.28N/A3.46+3.2x0.23+0.2x0.04N/AN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
PolyPid Ltd. PYPD FY2025 N/A -$34.2M N/A $129.3M —
Zentalis Pharmaceuticals, Inc. ZNTL FY2025 $0 -$137.1M N/A $133.6M —
MacroGenics, Inc. MGNX FY2025 $149.5M -$74.6M -49.9% $125.3M 59/100
Compass Therapeutics, Inc. CMPX FY2025 $0 -$66.5M N/A $123.9M —
Humacyte, Inc. HUMA FY2025 $2.0M -$40.8M N/A $123.7M 42/100
Invivyd, Inc. IVVD FY2025 $53.4M -$52.5M -98.3% $122.0M 70/100

Frequently Asked Questions

No, PolyPid Ltd. (PYPD) reported a net loss of $34.2M in fiscal year 2025.

PolyPid Ltd. (PYPD) reported diluted earnings per share of -$2.09 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PolyPid Ltd. (PYPD) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

PolyPid Ltd. (PYPD) has a return on equity of -311.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

PolyPid Ltd. (PYPD) recorded an outflow of $28.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

PolyPid Ltd. (PYPD) recorded an outflow of $27.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

PolyPid Ltd. (PYPD) had $22.3M in total assets as of fiscal year 2025, including both current and long-term assets.

PolyPid Ltd. (PYPD) invested $210K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

PolyPid Ltd. (PYPD) invested $23.8M in research and development during fiscal year 2025.

PolyPid Ltd. (PYPD) had 18M shares outstanding as of fiscal year 2025.

PolyPid Ltd. (PYPD) had a current ratio of 1.97 as of fiscal year 2025, which is generally considered healthy.

PolyPid Ltd. (PYPD) had a liabilities-to-equity ratio of 1.03 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

PolyPid Ltd. (PYPD) had a return on assets of -153.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

PolyPid Ltd. (PYPD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $129.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

PolyPid Ltd. (PYPD) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $129.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, PolyPid Ltd. (PYPD) held $6.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.9M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

PolyPid Ltd. (PYPD) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

PolyPid Ltd. (PYPD) reported a net loss of $34.2M while operations used $27.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

PolyPid Ltd. (PYPD) reported an operating loss of $33.0M against $874K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top